Atlas Trials

Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy

Clinical trial NCT05669768 · UNKNOWN

Trial details

NCT number
NCT05669768
Sponsor
Sun Yat-sen University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Ovarian Cancer
Start date
2023-01-01
Primary completion
2024-07-01
Enrollment
46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.